IL105078A - Pharmaceutical compositions containing 17-(3-pyridyl)- substituted steroids and some new compounds of this type - Google Patents
Pharmaceutical compositions containing 17-(3-pyridyl)- substituted steroids and some new compounds of this typeInfo
- Publication number
- IL105078A IL105078A IL105078A IL10507893A IL105078A IL 105078 A IL105078 A IL 105078A IL 105078 A IL105078 A IL 105078A IL 10507893 A IL10507893 A IL 10507893A IL 105078 A IL105078 A IL 105078A
- Authority
- IL
- Israel
- Prior art keywords
- carbon atoms
- pyridyl
- beta
- hydrogen atom
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929207057A GB9207057D0 (en) | 1992-03-31 | 1992-03-31 | Steroids |
GB929224880A GB9224880D0 (en) | 1992-11-27 | 1992-11-27 | Steroids |
Publications (2)
Publication Number | Publication Date |
---|---|
IL105078A0 IL105078A0 (en) | 1993-07-08 |
IL105078A true IL105078A (en) | 1997-11-20 |
Family
ID=26300621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL105078A IL105078A (en) | 1992-03-31 | 1993-03-16 | Pharmaceutical compositions containing 17-(3-pyridyl)- substituted steroids and some new compounds of this type |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0633893B1 (de) |
JP (1) | JP2742331B2 (de) |
KR (1) | KR100235135B1 (de) |
AT (1) | ATE186913T1 (de) |
AU (1) | AU668144B2 (de) |
CA (1) | CA2132449C (de) |
CZ (1) | CZ287434B6 (de) |
DE (2) | DE69327096T2 (de) |
DK (1) | DK0633893T3 (de) |
ES (1) | ES2138618T3 (de) |
GB (1) | GB2265624B (de) |
IL (1) | IL105078A (de) |
LU (1) | LU91911I2 (de) |
MX (1) | MX9301525A (de) |
NZ (1) | NZ249911A (de) |
WO (1) | WO1993020097A1 (de) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ273367A (en) * | 1993-09-30 | 1997-07-27 | British Tech Group | Preparation of 3<beta>-hydroxy (or lower acyloxy)-16,17-ene-17-(2-pyridyl)-substituted steroids using a palladium complex catalysed cross coupling reaction |
ES2133582T3 (es) * | 1993-10-27 | 1999-09-16 | Merrell Pharma Inc | Esteroides heterociclicos de c17 delta16-insaturados utiles como inhibidores de esteroide c17-20 liasa. |
CN1329394C (zh) | 2000-11-17 | 2007-08-01 | 武田药品工业株式会社 | 新咪唑衍生物、其制备方法及其用途 |
ATE502030T1 (de) | 2000-11-20 | 2011-04-15 | Takeda Pharmaceutical | Imidazolderivate, verfahren zu deren herstellung und deren verwendung |
EP1348706B1 (de) | 2000-12-08 | 2009-08-19 | Takeda Pharmaceutical Company Limited | Substituierte thiazolderivate mit 3-pyridylgruppen, verfahren zu deren herstellung und deren verwendung |
AU2002353147A1 (en) * | 2001-12-13 | 2003-06-30 | Abbott Laboratories | 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer |
AU2003278744B2 (en) * | 2002-08-28 | 2010-07-29 | Harbor Biosciences, Inc. | Therapeutic treatment methods |
US8569275B2 (en) | 2002-08-28 | 2013-10-29 | Harbor Therapeutics, Inc. | Steroids having 7-oxgen and 17-heteroaryl substitution |
GB0418900D0 (en) * | 2004-08-24 | 2004-09-29 | Btg Int Ltd | Novel salt forms |
SI1781683T1 (sl) * | 2004-08-24 | 2012-06-29 | Btg Int Ltd | Postopek za pripravo 17-vinil-triflatov kot intermediatov |
DE102006008074B4 (de) * | 2006-02-22 | 2013-08-14 | RUHR-UNIVERSITäT BOCHUM | Behandlung von Krebs mit Geruchsrezeptor-Liganden |
US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
KR20150108946A (ko) | 2006-08-25 | 2015-09-30 | 코우가 바이오테크놀로지, 인크. | 암을 치료하기 위한 방법 및 조성물 |
US20090124587A1 (en) * | 2007-07-12 | 2009-05-14 | Auerbach Alan H | METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS |
US20100048524A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
AU2010210422A1 (en) | 2009-02-05 | 2011-08-18 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens |
ES2475945T3 (es) | 2009-06-26 | 2014-07-11 | Novartis Ag | Derivados imidazolidin-2 -ona 1,3-disustituida como inhibidores de CYP 17 |
WO2011059969A2 (en) * | 2009-11-13 | 2011-05-19 | Tokai Pharmaceuticals, Inc. | Mammalian metabolites of steroids |
WO2011088160A2 (en) * | 2010-01-15 | 2011-07-21 | Biomarin Pharmaceutical Inc. | Novel cyp17 inhibitors |
KR101926320B1 (ko) | 2010-08-04 | 2018-12-06 | 펠피큐어 파마슈티걸즈 아이엔씨 | 전립선 암종의 치료를 위한 병용 요법 |
WO2012035078A1 (en) | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
CN102558274B (zh) * | 2010-12-08 | 2014-10-15 | 深圳万乐药业有限公司 | 一种适合工业化生产醋酸阿比特龙的合成方法 |
CA2819515A1 (en) * | 2010-12-16 | 2012-06-21 | Biomarin Pharmaceutical Inc. | Cyp11b, cyp17, and/or cyp21 inhibitors |
CN102558275A (zh) * | 2010-12-20 | 2012-07-11 | 天津药物研究院 | α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物 |
CA2834224A1 (en) | 2011-04-28 | 2012-11-01 | Novartis Ag | 17.alpha.-hydroxylase/c17,20-lyase inhibitors |
CN102321142A (zh) * | 2011-09-29 | 2012-01-18 | 重庆医药工业研究院有限责任公司 | 一种醋酸阿比特龙晶型及其制备方法 |
DE102011083725A1 (de) * | 2011-09-29 | 2013-04-04 | Bayer Pharma AG | Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
PL2766381T3 (pl) * | 2011-10-10 | 2016-12-30 | Sposób wytwarzania steroidów podstawionych w pozycji 17 | |
CN103059090B (zh) * | 2011-10-20 | 2016-06-22 | 连云港润众制药有限公司 | 醋酸阿比特龙草酸盐以及醋酸阿比特龙的纯化方法 |
MY175800A (en) | 2011-11-30 | 2020-07-09 | Astrazeneca Ab | Combination treatment of cancer |
EP2607371A1 (de) | 2011-12-23 | 2013-06-26 | Crystal Pharma, S.A.U. | Verfahren zur Herstellung von Abirateron und verwandten Verbindungen |
CN103172690B (zh) * | 2011-12-23 | 2016-08-24 | 重庆医药工业研究院有限责任公司 | 醋酸阿比特龙及其中间体的制备方法 |
CN103193849B (zh) * | 2012-01-04 | 2016-05-04 | 连云港润众制药有限公司 | 一种高纯度醋酸阿比特龙的制备方法 |
CN103254265B (zh) | 2012-02-21 | 2016-07-13 | 上海希迈医药科技有限公司 | 醋酸阿比特龙三氟乙酸盐及其制备方法和应用 |
CN102627681B (zh) * | 2012-03-23 | 2016-04-13 | 山东新时代药业有限公司 | 一种醋酸阿比特龙的制备方法 |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
CA2871314A1 (en) * | 2012-04-23 | 2013-10-31 | Alphora Research Inc. | Process for preparation of 17-substituted steroids |
MX2014014969A (es) | 2012-06-06 | 2015-03-13 | Novartis Ag | Combinacion de un inhibidor de la 17-alfa-hidroxilasa (c17,20-liasa) y un inhibidor especifico de la pi-3k para tratar una enfermedad tumoral. |
CN102731605B (zh) * | 2012-06-19 | 2016-04-13 | 鲁南制药集团股份有限公司 | 一种醋酸阿比特龙的纯化方法 |
PE20150353A1 (es) * | 2012-07-10 | 2015-03-28 | Bayer Pharma AG | Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos |
WO2014009436A1 (en) | 2012-07-11 | 2014-01-16 | Sandoz Ag | Nanosuspension of abiraterone acetate |
WO2014009434A1 (en) | 2012-07-11 | 2014-01-16 | Sandoz Ag | Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate |
WO2014009437A1 (en) | 2012-07-11 | 2014-01-16 | Sandoz Ag | Oxidation stability of abiraterone acetate |
EP2877482A4 (de) * | 2012-07-25 | 2016-04-06 | Mapi Pharma Ltd | Verfahren und zwischenprodukte zur herstellung von abirateron-acetat |
WO2014058785A1 (en) | 2012-10-10 | 2014-04-17 | Novartis Ag | Combination therapy |
ITMI20121788A1 (it) | 2012-10-22 | 2014-04-23 | Olon Spa | Procedimento per la purificazione di abiraterone acetato |
EP2917225A1 (de) | 2012-11-09 | 2015-09-16 | Synthon BV | Verfahren zur herstellung von abirateron-3-acetat |
WO2014071983A1 (en) | 2012-11-09 | 2014-05-15 | Synthon Bv | Process for making the 17-triflate intermediate of abiraterone-3-acetate |
TWI570131B (zh) * | 2012-11-13 | 2017-02-11 | 賽克系統公司 | 製備17-經取代類固醇之方法 |
WO2014075978A1 (en) | 2012-11-16 | 2014-05-22 | Synthon B.V. | Process for the production of abiraterone-3-acetate involving an enol trliflation reaction in the presence of an alkoxy-pyridine compound |
CN103059091B (zh) * | 2012-11-22 | 2017-04-19 | 常州靶点医药科技有限公司 | 一种避免重金属残留的醋酸阿比特龙的制备方法 |
CN103864878A (zh) * | 2012-12-12 | 2014-06-18 | 天津大学 | 阿比特龙醋酸酯的制备方法 |
WO2014102833A2 (en) | 2012-12-31 | 2014-07-03 | Hetero Research Foundation | Process for abiraterone acetate |
AU2014241816B9 (en) | 2013-03-14 | 2019-02-14 | Pellficure Pharmaceuticals Inc. | Novel therapy for prostate carcinoma |
EP4066841A1 (de) | 2013-03-14 | 2022-10-05 | University of Maryland, Baltimore | Mittel zur androgenrezeptor-abwärtsregelung und verwendungen davon |
ES2612780T3 (es) | 2013-04-19 | 2017-05-18 | Zach System | Proceso para producir una forma sólida de acetato de abiraterona |
JP2016527213A (ja) * | 2013-06-24 | 2016-09-08 | サン・ファーマシューティカル・インダストリーズ・リミテッドSun Pharmaceutical Industries Ltd. | アビラテロン酢酸エステルの製造方法 |
ES2663469T3 (es) | 2013-07-29 | 2018-04-12 | Industriale Chimica S.R.L. | Proceso para la preparación de abiraterona y acetato de abiraterona |
EP2890705B1 (de) | 2013-07-29 | 2016-04-13 | Industriale Chimica S.R.L. | Verfahren zur herstellung von abirateron oder abirateronacetat |
ITMI20131861A1 (it) * | 2013-11-08 | 2015-05-09 | Ind Chimica Srl | Processo per la preparazione di abiraterone e abiraterone acetato |
SG11201600525XA (en) | 2013-08-12 | 2016-02-26 | Tokai Pharmaceuticals Inc | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
CN104558091B (zh) * | 2013-10-16 | 2017-07-28 | 天津金耀集团有限公司 | 一种醋酸阿比特龙的合成方法 |
ES2741505T3 (es) | 2014-01-28 | 2020-02-11 | Olon Spa | Procedimiento para la preparación de acetato de abiraterona y sus productos intermedios |
CN103965282B (zh) | 2014-04-21 | 2016-01-20 | 武汉百科药物开发有限公司 | 一种醋酸阿比特龙的制备方法 |
US9315541B2 (en) | 2014-05-20 | 2016-04-19 | Olon S.P.A. | Process for the preparation of unsaturated trifluoromethanesulfonate steroid derivatives |
WO2016001208A1 (en) | 2014-06-30 | 2016-01-07 | Galenicum Health S.L. | Stable pharmaceutical compositions in the form of immediate release tablets |
CZ2014475A3 (cs) | 2014-07-09 | 2016-01-20 | Zentiva, K.S. | Způsob přípravy Abirateron acetátu o vysoké čistotě aplikovatelný v průmyslovém měřítku |
US10093620B2 (en) | 2014-09-12 | 2018-10-09 | Pellficure Pharmaceuticals, Inc. | Compositions and methods for treatment of prostate carcinoma |
CN106999432A (zh) | 2014-12-05 | 2017-08-01 | 阿拉贡药品公司 | 抗癌组合物 |
US10722527B2 (en) | 2015-04-10 | 2020-07-28 | Capsugel Belgium Nv | Abiraterone acetate lipid formulations |
CN108541255B (zh) * | 2016-02-02 | 2019-06-14 | 深圳市塔吉瑞生物医药有限公司 | 一种甾体类化合物及包含该化合物的组合物及其用途 |
CN109219437A (zh) | 2016-06-03 | 2019-01-15 | 阿拉贡药品公司 | 抗癌组合物 |
KR20240115925A (ko) | 2016-07-29 | 2024-07-26 | 얀센 파마슈티카 엔브이 | 전립선암의 치료 방법 |
WO2018080933A1 (en) | 2016-10-24 | 2018-05-03 | Pellficure Pharmaceuticals Inc. | Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione |
US11865215B2 (en) | 2018-04-26 | 2024-01-09 | Synthon B.V. | Tablet compositions comprising abiraterone acetate |
HU231297B1 (hu) | 2018-07-31 | 2022-09-28 | Richter Gedeon Nyrt | Stabil gyógyszerkészítmények és eljárás az előállításukra |
CN110272465A (zh) * | 2019-07-15 | 2019-09-24 | 成都贝诺科成生物科技有限公司 | 阿比特龙衍生物、其制备方法与应用 |
JP7526783B2 (ja) | 2019-08-08 | 2024-08-01 | ラークナ・リミテッド | 癌を処置する方法 |
EP3854384A1 (de) | 2020-01-27 | 2021-07-28 | Adamed Pharma S.A. | Pharmazeutische formulierung, die abirateronacetat umfasst |
BR112022021732A2 (pt) | 2020-05-08 | 2022-12-06 | Janssen Pharmaceutica Nv | Tratamentos de câncer de próstata com combinações de acetato de abiraterona e niraparibe |
EP3944860A1 (de) | 2020-07-30 | 2022-02-02 | Galenicum Health S.L.U. | Abirateron zur verwendung in einem verfahren zur behandlung von krebs |
WO2023148345A1 (en) | 2022-02-04 | 2023-08-10 | Janssen Pharmaceutica Nv | Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations |
CN116917306A (zh) * | 2022-02-18 | 2023-10-20 | 上海醇健医药技术有限公司 | 17-吡啶基-10α-甲基-甾体衍生物及中间体化合物、其制备方法、其用途、以及其药物组合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA882717B (en) * | 1987-04-22 | 1988-10-17 | Merrell Dow Pharmaceuticals Inc. | 17beta-(cyclopropylamino)-androst-5-eb-3beta-ol and related compounds useful as c17-20 lyase inhibitors |
US4966898A (en) * | 1989-08-15 | 1990-10-30 | Merrell Dow Pharmaceuticals Inc. | 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors |
-
1993
- 1993-03-15 CA CA002132449A patent/CA2132449C/en not_active Expired - Lifetime
- 1993-03-15 EP EP93906670A patent/EP0633893B1/de not_active Expired - Lifetime
- 1993-03-15 AT AT93906670T patent/ATE186913T1/de active
- 1993-03-15 AU AU37584/93A patent/AU668144B2/en not_active Expired
- 1993-03-15 DK DK93906670T patent/DK0633893T3/da active
- 1993-03-15 DE DE69327096T patent/DE69327096T2/de not_active Expired - Lifetime
- 1993-03-15 JP JP5517187A patent/JP2742331B2/ja not_active Expired - Lifetime
- 1993-03-15 GB GB9305269A patent/GB2265624B/en not_active Expired - Lifetime
- 1993-03-15 WO PCT/GB1993/000531 patent/WO1993020097A1/en active IP Right Grant
- 1993-03-15 CZ CZ19942337A patent/CZ287434B6/cs not_active IP Right Cessation
- 1993-03-15 NZ NZ249911A patent/NZ249911A/en not_active IP Right Cessation
- 1993-03-15 ES ES93906670T patent/ES2138618T3/es not_active Expired - Lifetime
- 1993-03-15 KR KR1019940703426A patent/KR100235135B1/ko not_active IP Right Cessation
- 1993-03-16 IL IL105078A patent/IL105078A/xx active Protection Beyond IP Right Term
- 1993-03-18 MX MX9301525A patent/MX9301525A/es active IP Right Grant
-
2011
- 2011-12-07 LU LU91911C patent/LU91911I2/fr unknown
-
2012
- 2012-01-12 DE DE201212000012 patent/DE122012000012I1/de active Pending
Also Published As
Publication number | Publication date |
---|---|
ATE186913T1 (de) | 1999-12-15 |
LU91911I2 (fr) | 2012-02-07 |
EP0633893B1 (de) | 1999-11-24 |
GB2265624A (en) | 1993-10-06 |
KR100235135B1 (ko) | 2000-01-15 |
EP0633893A1 (de) | 1995-01-18 |
GB2265624B (en) | 1995-04-19 |
GB9305269D0 (en) | 1993-05-05 |
DE69327096T2 (de) | 2000-06-21 |
CZ233794A3 (en) | 1995-02-15 |
CA2132449A1 (en) | 1993-10-14 |
CZ287434B6 (en) | 2000-11-15 |
AU3758493A (en) | 1993-11-08 |
DK0633893T3 (da) | 2000-04-17 |
DE122012000012I1 (de) | 2012-06-14 |
JPH07505377A (ja) | 1995-06-15 |
KR950700923A (ko) | 1995-02-20 |
JP2742331B2 (ja) | 1998-04-22 |
CA2132449C (en) | 2002-09-10 |
WO1993020097A1 (en) | 1993-10-14 |
IL105078A0 (en) | 1993-07-08 |
AU668144B2 (en) | 1996-04-26 |
NZ249911A (en) | 1996-06-25 |
ES2138618T3 (es) | 2000-01-16 |
MX9301525A (es) | 1994-02-28 |
DE69327096D1 (de) | 1999-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL105078A (en) | Pharmaceutical compositions containing 17-(3-pyridyl)- substituted steroids and some new compounds of this type | |
RU2210574C2 (ru) | Очищенные стероидсульфаматные соединения, эстрон-сульфаматы | |
CA2467222A1 (en) | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy | |
TW240215B (de) | ||
GEP20012530B (en) | Neuroactive Steroids of the Androstane and Pregnane Series | |
ZA899671B (en) | Phosphinic acid substituted steroids as inhibitors of steroid 5-alpha-reductase | |
MY114394A (en) | Estra-1,3,5 (10)-trien derivatives,process for their preparation and pharmaceutical compositions containing these compounds | |
IE46092L (en) | Esters of the androstane and oestrane series | |
ZA906710B (en) | 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha-reductase | |
PT92168B (pt) | Processo para a preparacao de composicoes farmaceuticas contendo derivados de nucleos de estrogenios para provocar a inibicao da actividade de esteroides sexuais | |
ZA929315B (en) | 17-spirofuran-3'-ylidene steroids. | |
KR880012633A (ko) | C_17 내지 C_20 리아제 억제제로서 유용한 17β-(사이클로프로필아미노)안드로스트-5-엔-3β-올 및 관련 화합물 | |
JP2000509388A (ja) | 抗炎症薬剤として有用なステロイドナイトレートエステル誘導体を含有する新規医薬組成物 | |
ATE111353T1 (de) | Makrolide zur behandlung reversibler obstruktiver atemwegserkrankungen. | |
PT88648A (pt) | Process for the preparation of new androstane 17-carboxylic acid esters and a pharmaceutical composition containing same | |
ZA899670B (en) | Phosphonic acid substituted steroids as steroid 5-alpha-reductase inhibitors | |
AP9300589A0 (en) | Novel 17a and 17b substituted acyl-3-carboxy 3,5-diene steroidal compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-a-reductase. | |
KR940701260A (ko) | 스테로이드 함유 안구용 약제조성물, 이것을 녹내장 치료에 사용하는 방법 및 이것의 제조방법 | |
OA06613A (fr) | Nouveaux dérivés d'amino-14 stéroïdes et procédé pour leur préparation. | |
HU9301814D0 (en) | D-homo-(16-en)-11beta-aryl-4-oestrenes as well as methods for producing and applying them as medicament | |
ES8707518A1 (es) | Un procedimiento para preparar nuevos derivados del 1,3-ben-zoxatiol | |
DE60031557D1 (de) | Steroide, ihre herstellung , pharmazeutische zusammensetzungen mit ihnen und verwendungen dieser verbindungen | |
TW343976B (en) | 17-substituted steroids useful in cancer treatment | |
WO1990015067A3 (fr) | NOUVEAUX PROCEDES D'OBTENTION DE 6-METHYL 19-NOR STEROIDES ET LEUR CONVERSION EN 19-NOR PREGNADIENES 17α-SUBSTITUES | |
GB961101A (en) | Steroid compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXTF | Application for patent extension filed | ||
EXTG | Extension of patent term granted |
Extension date: 20130916 |
|
PEL | Intention of commissioner to extend period of protection | ||
EXTN | Extension order renewed |